SILO · Silo Pharma, Inc.
$4.30
-0.16 (-3.59%)
At close · Jul 29
Going-concern doubt
— cleared May 14, 2026
The latest filing states the doubt was alleviated.
“The positive working capital serves to mitigate the conditions that historically raised substantial doubt about the Company's ability to continue as a going concern. The Company believes that it has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.”View the 10-Q filed May 14, 2026
Market Cap
$69.95M
Shares
16.27M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$72.1K
0%
FY2025
Net Income
-$4.23M
+3.8%
FY2025
Gross Margin
38.57%
-53.3pp
FY2025
Operating Margin
-5936.95%
+589.5pp
FY2025
Diluted EPS
-$7.50
+58%
FY2025
Operating Cash Flow
-$4.66M
-21.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $72.1K | $72.1K | $72.1K | $72.1K | $72.1K | — | $40.92K | $40.57K | — | — | — | — | — | |
| — | — | — | — | $72.64K | $1210 | — | — | — | — | — | — | — | |
| $1609 | — | — | — | — | -$3036 | — | — | — | — | — | — | — | |
| $63.52K | $44.3K | $5838 | $5838 | $5838 | $5004 | $176.13K | $27.39K | — | — | — | — | — | |
| $8579 | $27.81K | $66.26K | $66.26K | $66.26K | $66.26K | -$135.2K | $13.18K | — | — | — | — | — | |
| — | 38.57% | 91.9% | 91.9% | 91.9% | — | -330.38% | 32.49% | — | — | — | — | — | |
| $2.58M | $2.16M | $2.37M | $845.09K | $1.29M | $693.91K | $26.25K | — | — | — | — | — | — | |
| — | — | — | — | — | — | $120.84K | $87.01K | $76.08K | $29.56K | $10.3K | $39.45K | $49.8K | |
| — | — | — | $390.07K | $227.26K | $162.95K | $50.19K | — | — | — | — | — | — | |
| — | $11.44K | $6185 | — | — | — | — | $0 | $17.55K | — | — | — | — | |
| $4.79M | $4.31M | $4.77M | $3.92M | $3.69M | $2.81M | $2.2M | $943.59K | $594.24K | $490.87K | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $72.61K | $39.45K | $49.8K | |
| -$4.78M | -$4.28M | -$4.71M | -$3.86M | -$3.63M | -$2.74M | -$2.2M | -$930.4K | -$594.24K | -$490.87K | — | — | — | |
| — | -5936.95% | -6526.44% | -5347.41% | -5031.28% | — | -5380.15% | -2293.38% | — | — | — | — | — | |
| $38.61K | $37.3K | $5084 | $4869 | $2199 | $3036 | $80 | $0 | — | — | — | — | — | |
| — | $207 | — | — | — | — | — | — | — | — | $625 | — | — | |
| -$62.18K | $52.96K | $312.81K | $224.51K | -$279.73K | $6.93M | -$464.55K | -$82.89K | -$375.22K | $847.41K | — | — | — | |
| — | — | — | -$3118 | -$331.2K | $6.66M | — | — | — | — | — | — | — | |
| — | — | — | — | -$104.7K | $6.66M | — | — | — | — | $104.9K | — | — | |
| -$4.84M | -$4.23M | -$4.39M | -$3.63M | -$3.91M | $4.18M | -$2.67M | — | — | — | — | — | — | |
| — | — | — | — | — | $24.88K | — | — | — | — | — | — | — | |
| -$4.84M | -$4.23M | -$4.39M | -$3.7M | -$3.91M | $3.9M | -$3.04M | -$1.01M | -$969.46K | $356.54K | — | -$39.45K | -$49.8K | |
| — | -5863.5% | -6092.59% | -5132.57% | -5420.86% | — | -7422.52% | -2497.71% | — | — | — | — | — | |
| — | — | — | — | $3.91M | $3.9M | — | — | — | — | — | — | — | |
| — | — | — | — | -$3.91M | $2.5M | -$3.04M | — | — | — | — | — | — | |
| -$4.85M | -$4.22M | -$4.38M | -$3.71M | -$3.91M | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$7.50 | -$17.85 | -$18.00 | — | $30.00 | -$37.50 | — | -$15.00 | $7.50 | — | — | — |
| USD/shares | — | -$7.50 | -$17.85 | -$18.00 | — | $30.00 | -$37.50 | — | -$15.00 | $7.50 | — | — | — |
| shares | — | 558.82K | 245.36K | 205.32K | 152.28K | 126.49K | 87.94K | 31.29K | 65.47K | — | 43.25K | 40.84K | 40.84K |
| shares | — | 558.82K | 245.36K | 205.32K | 152.28K | 127.9K | 87.94K | 31.29K | 65.47K | 69.44K | — | 40.84K | 40.84K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.10×
EV/EBIT
—
Peer median 49.51×
P/E (TTM)
—
Peer median 3.23×
Peer medians compare against the 293 similar-size Biotechnology companies (of 521 listed).